Deena Goldwater1, Arun Karlamangla2, Sharon Stein Merkin2, Karol Watson3, Teresa Seeman2. 1. Department of Medicine, Division of Geriatrics, University of California, Los Angeles, 10945 Le Conte Ave, Ste 2339, Los Angeles, CA 90095; Department of Medicine, Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Ave, A2-237 Center for Health Sciences, Los Angeles, CA 90095. Electronic address: dgoldwater@mednet.ucla.edu. 2. Department of Medicine, Division of Geriatrics, University of California, Los Angeles, 10945 Le Conte Ave, Ste 2339, Los Angeles, CA 90095. 3. Department of Medicine, Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Ave, A2-237 Center for Health Sciences, Los Angeles, CA 90095.
Abstract
PURPOSE: To understand if baseline levels of the anti-inflammatory cytokine interleukin-10 (IL-10) are associated with either subclinical atherosclerosis or risk for adverse cardiovascular (CV) events. METHODS: The study included 930 adults from the Multi-Ethnic Study of Atherosclerosis (MESA) ancillary Stress Study. Participants, age 48-90 years at enrollment, were followed for an average of 10.2 years. IL-10 level was measured at the initial Stress Study visit. Cardiovascular outcomes were defined as composite CV death, myocardial infarction, stroke, stroke death, and resuscitated cardiac arrest. Coronary calcification was determined by Agatston coronary artery calcium (CAC) score. The association between IL-10 level and CV event risk was evaluated by Cox proportional hazard modeling, while that of IL-10 level and CAC presence and amount was determined with prevalence risk ratio (PRR) and linear regression modeling, respectively. Models were adjusted for CV risk factors and proinflammatory biomarkers. RESULTS: After full adjustment, IL-10 level did not predict CV events (HR 1.19, 95%CI 0.89, 1.60) and was not associated with CAC prevalence (PRR 1.00, 95%CI 0.94, 1.07), nor amount of CAC in those with nonzero CAC (β -0.01, 95%CI -0.23, 0.21). CONCLUSION: In individuals without clinical heart disease, baseline IL-10 level appears unrelated to risk of CV events and is a poor marker of subclinical coronary atherosclerosis.
PURPOSE: To understand if baseline levels of the anti-inflammatory cytokine interleukin-10 (IL-10) are associated with either subclinical atherosclerosis or risk for adverse cardiovascular (CV) events. METHODS: The study included 930 adults from the Multi-Ethnic Study of Atherosclerosis (MESA) ancillary Stress Study. Participants, age 48-90 years at enrollment, were followed for an average of 10.2 years. IL-10 level was measured at the initial Stress Study visit. Cardiovascular outcomes were defined as composite CV death, myocardial infarction, stroke, stroke death, and resuscitated cardiac arrest. Coronary calcification was determined by Agatston coronary artery calcium (CAC) score. The association between IL-10 level and CV event risk was evaluated by Cox proportional hazard modeling, while that of IL-10 level and CAC presence and amount was determined with prevalence risk ratio (PRR) and linear regression modeling, respectively. Models were adjusted for CV risk factors and proinflammatory biomarkers. RESULTS: After full adjustment, IL-10 level did not predict CV events (HR 1.19, 95%CI 0.89, 1.60) and was not associated with CAC prevalence (PRR 1.00, 95%CI 0.94, 1.07), nor amount of CAC in those with nonzero CAC (β -0.01, 95%CI -0.23, 0.21). CONCLUSION: In individuals without clinical heart disease, baseline IL-10 level appears unrelated to risk of CV events and is a poor marker of subclinical coronary atherosclerosis.
Authors: Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Stephan Fichtlscherer; Eric Boersma; Maarten L Simoons; Andreas M Zeiher Journal: Circulation Date: 2003-03-31 Impact factor: 29.690
Authors: Dorette Raaz-Schrauder; Lutz Klinghammer; Christina Baum; Thomas Frank; Piotr Lewczuk; Stephan Achenbach; Iwona Cicha; Christian Stumpf; Jens Wiltfang; Johannes Kornhuber; Werner G Daniel; Christoph D Garlichs Journal: Cytokine Date: 2011-12-14 Impact factor: 3.861
Authors: Jason S Stumhofer; Jonathan S Silver; Arian Laurence; Paige M Porrett; Tajie H Harris; Laurence A Turka; Matthias Ernst; Christiaan J M Saris; John J O'Shea; Christopher A Hunter Journal: Nat Immunol Date: 2007-11-11 Impact factor: 25.606
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Gordon Lowe; Mark B Pepys; Simon G Thompson; Rory Collins; John Danesh Journal: Lancet Date: 2009-12-22 Impact factor: 79.321
Authors: Debora Kamin Mukaz; Mansour Gergi; Insu Koh; Neil A Zakai; Suzanne E Judd; Michelle Sholzberg; Lisa Baumann Kreuziger; Kalev Freeman; Christos Colovos; Nels C Olson; Mary Cushman Journal: Res Pract Thromb Haemost Date: 2021-12-07